This Week at Peak Human: Plant vs. Animal Protein — Does the Source Change the Result?

A note from Dr. Goel

This week I'm digging into something I get asked about constantly: does protein source actually matter for building muscle? I've also got updates on an oral anti-inflammatory drug's Phase 2 data, what HHS said about BPC-157, and refreshed evidence on tirzepatide, astaxanthin, and lithium orotate, plus a new training article on the blog. Here's what's new this week, and what I'd actually pay attention to.

— Dr. Sanjeev Goel

🔬 This week's deep dive: Plant vs. Animal Protein

If you've ever been told that plant protein "doesn't count" for building muscle, this is the piece to read. I pulled together a line of matched-protein resistance-training trials that put plant and animal protein sources head-to-head on muscle protein synthesis — and the honest answer is more nuanced than either camp's talking points.

What makes it different: The case against plant protein has always come down to leucine — the amino acid that triggers muscle protein synthesis. Whey is unusually leucine-dense; most plant proteins are not. But that hides the variable that actually matters: total protein and leucine intake across the day, not the source label.

What the research shows:

Leucine gap, quantified: Gram for gram, plant protein isolates carry meaningfully less leucine; it takes roughly 54g of hemp protein to match the leucine in just 25g of whey.

Matched-protein trials: When total protein is matched at 1.6–2 g/kg bodyweight/day, vegans and omnivores gained the same 1.2 kg of leg lean mass over 12 weeks.

Where source still matters: The real gaps show up at the margins: low-leucine single meals, or total daily protein falling short of 1.6 g/kg. Source is a tiebreaker only once total intake is right.

The honest caveats: This is a narrow, well-controlled setup. Whole-food plant proteins (beans, lentils, tofu) behave differently than the isolates used in most trials — if eating those rather than engineered blends, you likely need somewhat more total protein.

My take: Source matters less than most people assume once you control for total protein and leucine content — but it isn't zero. If you're plant-based and training hard, the fix isn't switching to animal protein; it's hitting your total protein target consistently and making sure some meals include a leucine-dense source.

📊 Site update: An Oral Anti-Inflammatory Drug Just Finished Phase 2 Enrollment

For the first time, a dedicated oral NLRP3 inflammasome inhibitor — the same pathway the CANTOS trial targeted with an injectable biologic — is far enough along in human trials to talk about real data. BioAge Labs' BGE-102 reported suppressing IL-1β by up to 98% and hsCRP by roughly 86% in Phase 1 (company-reported, not peer-reviewed), and its ~160-person Phase 2 trial (QUELL-CV) completed enrollment in early November, topline data expected Q4 2026.

This is an investigational drug — not approved, not something I can recommend today. CANTOS is the right caution: lowering inflammation can help the heart and still raise other risks. I'll report back when QUELL-CV's data is public.

⚖️ Site update: What HHS Actually Said About BPC-157

Two issues ago I flagged peptide compounding rules as a real cliffhanger. On October 30, HHS published an interim enforcement-discretion policy naming six peptides — including BPC-157, Epitalon, KPV, MOTS-c, Semax, and TB-500 — as eligible for 503A pharmacy compounding under physician oversight. To be clear: enforcement discretion is not FDA approval, and it says nothing about efficacy.

📊 Site update: Tirzepatide's Growing Evidence Base

SURMOUNT-5 (NEJM, 2025, n=751): tirzepatide produced greater average weight loss than semaglutide over 72 weeks (20.2% vs. 13.7%). SUMMIT trial: tirzepatide reduced cardiovascular death and heart-failure events in obesity-related HFpEF patients (HR 0.62). Prescription medication, used under medical supervision only.

🧪 Site update: New Astaxanthin Data on Blood Sugar and Lipids

A 2026 meta-analysis of 9 RCTs in 403 adults with prediabetes/T2D found astaxanthin associated with lower fasting glucose (−16.1 mg/dL), triglycerides (−20.9 mg/dL), LDL (−9.4 mg/dL), and HbA1c (−0.34%).

🧠 Site update: Lithium Orotate's Early Alzheimer's Signal

I also updated our lithium orotate entry this week. A 2025 Nature paper found that brain lithium depletion is one of the earliest molecular changes seen in Alzheimer's — and in mice, replacing it with lithium orotate specifically (not other lithium salts tested) reversed the pathology. A small 2026 JAMA Neurology pilot trial (80 adults with mild cognitive impairment, using lithium carbonate — a different salt) found verbal-memory decline nearly cut in half over two years, though the result landed just outside the trial's own strict pre-specified significance threshold.

This is early, hypothesis-generating evidence, not proof. The human trial used a different lithium salt than the one tested in mice, the pilot was small, and its own statistics call it borderline. I would not call this settled science — I'd call it one of the more interesting signals in brain-aging research right now, and worth watching rather than acting on.

📝 New on the blog

"Full Body vs. Split — What Actually Builds Muscle?"

📰 Longevity news worth your minute

hs-CRP keeps predicting heart disease decades out: a 30-year, 27,939-woman NEJM study found hs-CRP, LDL-C, and Lp(a) each independently predicted later cardiovascular events — hs-CRP was the strongest single predictor.

An old osteoporosis drug keeps showing up in metabolic data: a 2024 cohort of ~46,000 patients/arm found denosumab associated with lower new-onset T2D and mortality vs. bisphosphonates (observational).

⚕️ Important disclaimer

This newsletter is for educational purposes only and is not medical advice. Compounds discussed may be investigational and not FDA-approved. Nothing here is a recommendation to start, stop, or change any treatment. Peptide and metabolic therapies carry real risks and should only be used under qualified medical supervision. Always consult your physician before making health decisions.